目的 探討頭風(fēng)痛膠囊聯(lián)合倍他司汀治療血管性頭痛的療效及對血清細胞因子的影響。方法 選取2019年5月—2020年5月在天津醫(yī)科大學(xué)寶坻臨床學(xué)院進行診斷治療的122例血管性頭痛患者，依據(jù)藥物使用的差別將所有患者分成對照組和治療組，每組各61例。對照組口服鹽酸倍他司汀片，8 mg/次，3次/d；治療組在對照組治療基礎(chǔ)上口服頭風(fēng)痛膠囊，1.5 g/次，2次/d。兩組均治療8周。觀察兩組的臨床療效和臨床癥狀緩解情況，比較兩組生活質(zhì)量評分（SF-36）、匹茲堡睡眠質(zhì)量指數(shù)量表（PSQI）、疼痛視覺模擬評分（VAS）、血清β內(nèi)咖啡肽（β-EP）、同型半胱氨酸（Hcy）、降鈣素基因相關(guān)肽（CGRP）、P物質(zhì)（SP）水平。結(jié)果 治療后，治療組總有效率是96.72%，顯著高于對照組的83.61%（P<0.05）。治療后，兩組頭痛發(fā)作次數(shù)顯著減少，頭痛發(fā)作持續(xù)時間明顯縮短（P<0.05）；治療后，治療組頭痛發(fā)作次數(shù)少于對照組，頭痛發(fā)作持續(xù)時間短于對照組（P<0.05）。治療后兩組SF-36評分顯著升高，但PSQI評分、VAS評分都明顯降低（P<0.05）；治療后，治療組相關(guān)量表評分改善情況優(yōu)于對照組（P<0.05）。治療后兩組血清β-EP顯著升高，但Hcy、CGRP、SP水平均顯著降低（P<0.05）；治療后，治療組血清學(xué)指標改善優(yōu)于對照組（P<0.05）。結(jié)論 頭風(fēng)痛膠囊聯(lián)合倍他司汀治療血管性頭痛療效顯著，同時還能改善患者臨床體征和生活質(zhì)量，調(diào)節(jié)血清學(xué)指標水平，具有一定的臨床推廣應(yīng)用價值。

Objective To investigate the effect of Toufengtong Capsules combined with betahistine in treatment of vascular headache and its effect on serum cytokines.Methods A total of 122 patients with vascular headache who were diagnosed and treated in Baodi Clinical College of Tianjin Medical University from May 2019 to May 2020 were selected. All the patients were divided into control group and treatment group according to the difference of drug use, with 61 cases in each group. Patients in the control group were po administered with Betahistine Hydrochloride Tablets, 8 mg/time, three times daily. Patients in the treatment group were po administered with Toufengtong Capsules on the basis of the control group, 1.5 g/time, twice daily. Patients in two groups were treated for 8 weeks. After treatment, the clinical efficacy and the remission of clinical symptoms in two groups was evaluated, and the levels of life quality score (SF-36), Pittsburgh Sleep Quality Index (PSQI), visual analog scale of pain (VAS), serum β-caffeinin (β-EP), homocysteine (Hcy), calcitonin gene-related peptide (CGRP), and substance P (SP) levels were compared between the two groups.Results After treatment, the total effective rate of the treatment group was 96.72%, which was significantly higher than that of the control group (83.61%,P<0.05). After treatment, the frequency and duration of headache attacks in both groups were significantly decreased (P<0.05). After treatment, the frequency and duration of headache attacks in the treatment group were less than those in the control group (P<0.05). After treatment, SF-36 scores in both groups were significantly increased, but PSQI scores and VAS scores were significantly decreased (P<0.05). After treatment, the improvement of related scale scores in the treatment group was better than that in the control group (P<0.05). After treatment, serum β-EP in both groups was significantly increased, but the levels of Hcy, CGRP and SP were significantly decreased (P<0.05). After treatment, the improvement of serological indexes in the treatment group was better than that in the control group (P<0.05).Conclusion Toufengtong Capsules combined with betahistine has curative effect in treatment of vascular headache, and can also improve the clinical signs and life quality of patients, and also can regulate the level of serological indicators, which has a certain value of clinical application.

R971